TrialCancer medicine2020

Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.

Akira Ooki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.